Weight Loss and Obesity Management Market Size – Product and Services (Supplement, Drug [GLP-1 Receptor Agonist, Lipase Inhibitor, Serotonin Receptor Agonist], Equipment [Fitness Monitoring, Surgical], Service), Age Group & Global Forecast, 2024 – 2032

Weight Loss and Obesity Management Market Size

Weight Loss And Obesity Management Market was valued at USD 232.4 billion in 2023 and is anticipated to showcase about 8.6% CAGR from 2024 to 2032. Increasing prevalence of obesity and overweight, growing approval for obesity treatment drugs, and increasing awareness towards fitness activities is driving the significant growth. Additionally, growing demand for bariatric surgery to treat extreme obesity is also supplementing the market growth.
 

The weight loss and obesity management market encompass products, services, and interventions designed to address overweight and obesity issues in individuals. This market includes a wide range of offerings aimed at helping people achieve and maintain healthy weight levels, manage associated health conditions, and improve overall well-being.
 

Weight Loss and Obesity Management Market Trends

• Advances in surgical techniques and improved safety profiles are leading to an increased acceptance for surgical interventions among extremely obese patients. Availability of advanced surgical options such as biliopancreatic diversion with duodenal switch, and single anastomosis duodenal switch have revolutionized bariatric surgeries. Growing popularity of these procedures can be attributed to their enhanced effectiveness and reduced risk of weight regain, which is contributing to an increasing growth in the weight loss and obesity management market.
   
• The use of digital health technologies, encompassing mobile applications, wearable devices, and online platforms is becoming more prevalent in the field of weight management. These innovative tools provide a range of features, including calorie tracking, meal planning, fitness monitoring, behavior modification support, and remote coaching.
   
• Increasing availability of prescription medication for obesity treatment is also driving their adoption worldwide. By March 2023, U.S. FDA has approved 5 prescription medications including orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, and semaglutide for long term use. Later, in November 2023, Mounjaro, a new drug to treat diabetes was also approved by U.S. FDA for use in weight loss. Along with existing GLP-1 receptor agonist, increasing availability of new obesity treatment drugs are offering lucrative growth opportunities to the pharmaceutical companies globally.
   

Weight Loss and Obesity Management Market Analysis

Based on product & services, the drugs segment is further segmented into GLP-1 receptor agonists, lipase inhibitors, combination drugs, serotonin receptor agonists, and other drugs. Similarly, equipment segment is also further segmented as fitness equipment, fitness monitoring equipment, surgical equipment, and other equipment. The supplements segment held the majority of market share of about 48.3% in 2023.
 

• The dominating share of supplement segment can be attributed to their easy availability over the counter without requiring the prescriptions from medical practitioners. This makes them easily accessible to obese patients.
   
• Availability of weight loss supplements as herbal/natural products is gaining increasing popularity among obese patients that perceives supplements as a safer alternative to prescription drugs. While efficacy and safety vary among supplements, the perception of obese patients towards supplements and strong brand marketing by supplement manufacturers is contributing to significantly high adoption of supplements in weight loss and obesity management industry.
   
• Moreover, supplement industry is less regulated in comparison to pharmaceuticals, this allows the manufacturers to quickly introduce new products into the market with less regulatory hurdles.

Based on age group, the weight loss and obesity management market is classified into adults and children. The adult segment dominated the market with a revenue of about USD 206.4 billion in 2023.
 

• Leading share of adult segment can be attributed to high prevalence of obesity among adults. According to the World Health Organization in 2022, about 2.5 billion adults (18 years and older) were overweight in comparison to 427 children under 5 years and 5-19 years of age.
   
• Moreover, increasing lifestyle related disorders among adult population is also driving an increasing prevalence of obesity, thereby driving the demand for weight loss and obesity management in the segment.

North America weight loss and obesity management market accounted for 42.6% of market share in global market in 2023 and is predicted to reach USD 199.4 billion by 2032.
 

• Leading share of North America can be attributed to high prevalence of obesity and increasing awareness towards fitness activities. Owing to increasing burden of obesity, governments are promoting healthy lifestyle practices and nutritional awareness through campaigns and national programs such as Active People, Healthy Nation, a Center for Disease Control and Prevention- led initiative aimed at increasing the physical activity levels of 27 million Americans by 2027. Increasing awareness towards healthy lifestyle is contributing to an increasing demand for obesity treatment supplements, meals, and medications.
   
• Furthermore, presence of established healthcare infrastructure and strong nutraceutical and pharmaceutical industry is aiding to an easy availability of treatment options for obese and overweight patients. According to the U.S. FDA, by April 2024, about 11 medications were approved for weight loss treatments including both short term and long-term use.
   

The U.S. weight loss and obesity management market was valued at USD 87 billion in 2023 and is anticipated to grow at a CAGR of 8.2% through 2032.
 

• Increasing growth in extreme obesity in the U.S. has surged the demand for bariatric surgeries. According to the ASMBS, total number of bariatric surgeries in the U.S. has increased from 158,000 in 2011 to 279,967 in 2022. Increase in surgical interventions is driving the demand for surgical equipment, thereby contributing to a leading share of U.S. market.
   
• Furthermore, increasing adoption of nutraceutical-based treatments for weight loss in the country is also aiding to the revenue growth in the weight loss and obesity management industry. According to a 2022 article from National Institutre of Health, about 15% of the U.S. adults have utilized a weight-loss dietary supplement at some stage in their lives.
   

Germany weight loss and obesity management market is expected to show significant growth opportunities during 2024 to 2032.
 

• Germany is witnessing increasing growth in obesity management services due to the presence of large number of private organizations and clinics such as Földiklinik, Neo Fatbury, and YourWeightcare. These organizations and clinics are offering nutritional advice, exercise programs, psychological support, and diagnostics and treatment consultation. Increasing adoption of such obesity management services are driving the revenue growth in Germany.
   
• Furthermore, growing health expenditure on obesity treatment is also contributing to the regional revenue share. According to the Organisation for Economic Co-operation and Development, in 2019, overweight accounts for 10.7% of health expenditure in Germany.
   

India weight loss and obesity management market is anticipated to grow remarkable growth over the coming years.
 

• Increasing burden of obesity together with increasing availability of prescription medication is driving the revenue growth in the India weight loss and obesity management business.
   
• For instance, according to the Global Obesity Observatory of World Obesity Federation, in 2019, the economic impact of obesity and overweight in India was anticipated to remain at USD 28.95 billion. As a result pharmaceutical companies are increasingly focusing towards launching new prescription medication for obesity treatment in India. For instance, Novo Nordisk launched semaglutide in January 2022.
   
• Additionally, government campaign to reduce obesity such as Rashtriya Kishor Swasthya Karyakram and Eat Right India Movement are also contributing towards increased awareness for weight loss and obesity management in the country, thereby contributing to the overall market growth.
   

Weight Loss and Obesity Management Market Share

The market for weight loss and obesity management is characterized by fragmentation due to the presence of numerous established and small-scale vendors worldwide offering variety of products and services targeting different aspects of weight loss and obesity management. These variety of products include drugs, surgical equipment, and fitness equipment, among others. The fragmentation of the market is further amplified by the diversity of consumer preferences, healthcare needs, and regulatory landscapes across different regions. Established market players possess significant financial resources for investment in research and development to develop and launch new obesity treatment products. On the other hand, smaller companies rely on low pricing strategies to compete with established players.
 

Weight Loss and Obesity Management Market Companies

Prominent players operating in the weight loss and obesity management industry include:

• Allurion
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Eisai Co., Ltd.
• Equinox Inc.
• FOUND
• Herbalife International of America, Inc.
• Johnson & Johnson Services Inc. (Ethicon Inc.)
• Kellogg Co.
• Lifetime Fitness Inc.
• Medtronic plc
• Novo Nordisk A/S
• Nutrisystem, Inc.
• OptiBiotix Online
• PRISTYN CARE
• Roman Health Ventures Inc.
• Takeda Pharmaceutical Company Ltd.
• Teleflex Inc.
• VIVUS LLC.
• WW International, Inc.
   

Weight Loss and Obesity Management Industry News

• In February 2024, Herbalife International of America, Inc. announced the launch of Herbalife GLP-1 Nutrition Companion, a dietary and supplement product designed to cater to the nutritional requirements of patients using GLP-1 and other weight-loss medications.
   
• In January 2024, Lifetime Fitness Inc. announced the launch of MIORA Longevity and Performance, a personalized services that aims to target longevity, performance, weight loss.
   

This weight loss and obesity management market research report include an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product & Services

• Supplements
• Drugs
  • GLP-1 receptor agonists
  • Lipase inhibitors
  • Combination drugs
  • Serotonin receptor agonists
  • Other drugs 
• Equipment
  • Fitness equipment
  • Fitness monitoring equipment
  • Surgical equipment
  • Other equipment
• Services

Market, By Age Group

• Adults
• Children

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa